25402624|t|Forxiga (dapagliflozin): Plausible role in the treatment of diabetes-associated neurological disorders.
25402624|a|Numerous clinical and epidemiological studies have provided direct evidence to strengthen the link between type 2 diabetes (T2D) and Alzheimer's disease (AD). The possibility that T2D patients might be at increased risk in developing AD has serious societal implications. Sodium glucose co-transporter 2 (SGLT2) is one of the best targets in the treatment of diabetes, whereas acetylcholinesterase (AChE) has long been regarded as a therapeutic target for AD. This study explores the molecular interactions between AChE and SGLT2 with a new US Food and Drug Administration approved antidiabetic drug Forxiga (dapagliflozin) to explore a possible link between the treatments of AD and diabetes. Docking study was performed using "Autodock4.2." Hydrophobic and cation-pi interactions play an important role in the correct positioning of dapagliflozin within the catalytic site (CAS) of SGLT2 and AChE enzymes to permit docking. Free energy of binding (DeltaG) of "dapagliflozin-SGLT2" and "dapagliflozin-CAS domain of AChE" interactions was found to be -6.25 and -6.28 kcal/mol, respectively. Hence, dapagliflozin might act as a potent dual inhibitor of SGLT2 and AChE. The results described herein may form the basis of future dual therapy against diabetes-associated neurological disorders. 
25402624	0	7	Forxiga	Disease	
25402624	9	22	dapagliflozin	Chemical	MESH:C529054
25402624	60	68	diabetes	Disease	MESH:D003920
25402624	80	102	neurological disorders	Disease	MESH:D009461
25402624	211	226	type 2 diabetes	Disease	MESH:D003924
25402624	228	231	T2D	Disease	MESH:D003924
25402624	237	256	Alzheimer's disease	Disease	MESH:D000544
25402624	258	260	AD	Disease	MESH:D000544
25402624	284	287	T2D	Disease	MESH:D003924
25402624	288	296	patients	Species	9606
25402624	338	340	AD	Disease	MESH:D000544
25402624	376	407	Sodium glucose co-transporter 2	Gene	6524
25402624	409	414	SGLT2	Gene	6524
25402624	463	471	diabetes	Disease	MESH:D003920
25402624	481	501	acetylcholinesterase	Gene	43
25402624	503	507	AChE	Gene	43
25402624	560	562	AD	Disease	MESH:D000544
25402624	619	623	AChE	Gene	43
25402624	628	633	SGLT2	Gene	6524
25402624	704	711	Forxiga	Chemical	MESH:C529054
25402624	713	726	dapagliflozin	Chemical	MESH:C529054
25402624	781	783	AD	Disease	MESH:D000544
25402624	788	796	diabetes	Disease	MESH:D003920
25402624	939	952	dapagliflozin	Chemical	MESH:C529054
25402624	988	993	SGLT2	Gene	6524
25402624	998	1002	AChE	Gene	43
25402624	1066	1079	dapagliflozin	Chemical	MESH:C529054
25402624	1080	1085	SGLT2	Gene	6524
25402624	1092	1105	dapagliflozin	Chemical	MESH:C529054
25402624	1120	1124	AChE	Gene	43
25402624	1202	1215	dapagliflozin	Chemical	MESH:C529054
25402624	1256	1261	SGLT2	Gene	6524
25402624	1266	1271	AChE.	Gene	43
25402624	1351	1359	diabetes	Disease	MESH:D003920
25402624	1371	1393	neurological disorders	Disease	MESH:D009461
25402624	Negative_Correlation	MESH:C529054	6524
25402624	Association	MESH:D003920	43
25402624	Association	MESH:D003920	6524
25402624	Negative_Correlation	MESH:C529054	MESH:D000544
25402624	Negative_Correlation	MESH:C529054	MESH:D009461
25402624	Association	MESH:D000544	43
25402624	Negative_Correlation	MESH:C529054	43
25402624	Negative_Correlation	MESH:C529054	MESH:D003920
25402624	Association	MESH:D009461	43

